Atara Biotherapeutics IncATRA
Price$8.50

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $6.2M-95.2% YoYTTM through 30 Jun 2026
Net Income -$16.7MTTM through 30 Jun 2026
Free Cash Flow -$22.5MTTM through 30 Jun 2026

Margins

Current
Gross Margin76.0%
EBITDA Margin-227.6%
Operating Margin-660.5%
Net Margin-269.4%

Returns

25.4%ROE
-47.3%ROA

Balance Sheet Health

Current Ratio2.16x
Net Debt$41.5M
Cash & Equivalents$3.2M

Quality Metrics

Altman Z-Score-135.86
Piotroski F-Score1 / 9
FCF Margin-364.0%
Earnings-Beat Rate66.7%

Multi-Year Trend

Revenue
'23'24'25
FY2025: $120.8M
Diluted EPS-$1.54TTM
'20'21'22'23'24'25
FY2025: $2.57

Dividend

No dividend

Capital Allocation

R&D Spend$4.2M
Capex Intensity10.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.